These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26182225)

  • 1. Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease.
    Malpas CB; Saling MM; Velakoulis D; Desmond P; Hicks RJ; OʼBrien TJ;
    J Comput Assist Tomogr; 2015; 39(4):559-64. PubMed ID: 26182225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain Metabolism of Less-Educated Patients With Alzheimer Dementia Studied by Positron Emission Tomography.
    Huang YC; Yen PS; Wu ST; Chen JT; Hung GU; Kao CH; Chen TY; Ho FM
    Medicine (Baltimore); 2015 Jul; 94(30):e1252. PubMed ID: 26222866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional neuroanatomy of verbal memory in Alzheimer's disease: [
    Staffaroni AM; Melrose RJ; Leskin LP; Riskin-Jones H; Harwood D; Mandelkern M; Sultzer DL
    J Clin Exp Neuropsychol; 2017 Sep; 39(7):682-693. PubMed ID: 27876444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease.
    Thomas BA; Erlandsson K; Modat M; Thurfjell L; Vandenberghe R; Ourselin S; Hutton BF
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1104-19. PubMed ID: 21336694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment.
    Fellgiebel A; Siessmeier T; Scheurich A; Winterer G; Bartenstein P; Schmidt LG; Müller MJ
    Biol Psychiatry; 2004 Aug; 56(4):279-83. PubMed ID: 15312816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer's disease.
    Musiek ES; Saboury B; Mishra S; Chen Y; Reddin JS; Newberg AB; Udupa JK; Detre JA; Hofheinz F; Torigian D; Alavi A
    Hell J Nucl Med; 2012; 15(3):190-6. PubMed ID: 23106049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparability of [
    Rodriguez-Vieitez E; Leuzy A; Chiotis K; Saint-Aubert L; Wall A; Nordberg A
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional fluorodeoxyglucose metabolism and instrumental activities of daily living across the Alzheimer's disease spectrum.
    Roy K; Pepin LC; Philiossaint M; Lorius N; Becker JA; Locascio JJ; Rentz DM; Sperling RA; Johnson KA; Marshall GA
    J Alzheimers Dis; 2014; 42(1):291-300. PubMed ID: 24898635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
    Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction.
    Yanase D; Matsunari I; Yajima K; Chen W; Fujikawa A; Nishimura S; Matsuda H; Yamada M
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):794-805. PubMed ID: 15759148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
    Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
    J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial volume correction in longitudinal tau PET studies: is it really needed?
    Costoya-Sánchez A; Moscoso A; Sobrino T; Ruibal Á; Grothe MJ; Schöll M; Silva-Rodríguez J; Aguiar P;
    Neuroimage; 2024 Apr; 289():120537. PubMed ID: 38367651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose Reduction in Brain [
    Soret M; Piekarski E; Yeni N; Giron A; Maisonobe JA; Khalifé M; Zaslavsky C; Bertaux M; Habert MO; Kas A
    Mol Imaging Biol; 2020 Jun; 22(3):695-702. PubMed ID: 31286349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease.
    Fouquet M; Desgranges B; Landeau B; Duchesnay E; Mézenge F; de la Sayette V; Viader F; Baron JC; Eustache F; Chételat G
    Brain; 2009 Aug; 132(Pt 8):2058-67. PubMed ID: 19477964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.